Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$6.78 - $12.28 $343,068 - $621,368
-50,600 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$7.65 - $15.29 $364,384 - $728,293
-47,632 Reduced 48.49%
50,600 $461,000
Q4 2021

Feb 14, 2022

BUY
$13.13 - $24.52 $1.29 Million - $2.41 Million
98,232 New
98,232 $1.47 Million
Q3 2020

Nov 13, 2020

SELL
$32.38 - $44.96 $6.48 Million - $8.99 Million
-200,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$18.39 - $54.04 $3.68 Million - $10.8 Million
200,000 New
200,000 $8.56 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $269M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.